Journal of the American Society of Hypertension
Volume 2, Issue 1 , Pages 44-53 , January 2008

Estimated prevalence of uncontrolled hypertension and multiple cardiovascular risk factors and their associated risk of coronary heart disease in the United States

  • Joshua S. Benner, PharmD, ScD

      Affiliations

    • IMS Health, Inc., Arlington, Virginia, USA
    • Drs. Benner, Smith, and Klingman are all employees of IMS Health, Inc, a health information services and consulting firm. They have provided consulting services to manufacturers of antihypertensive and lipid-lowering therapies, including Pfizer Inc., Schering-Plough Corporation, and AstraZeneca Pharmaceuticals LP.
    • Corresponding Author InformationCorresponding author: Joshua S. Benner, PharmD, ScD, Principal, IMS Health, Inc., 300 N. Washington Street, Suite 303, Arlington, Virginia 22046. Tel: 703-286-2868; fax: 703-286-2899.
  • ,
  • Timothy W. Smith, BA

      Affiliations

    • IMS Health, Inc., Arlington, Virginia, USA
    • Drs. Benner, Smith, and Klingman are all employees of IMS Health, Inc, a health information services and consulting firm. They have provided consulting services to manufacturers of antihypertensive and lipid-lowering therapies, including Pfizer Inc., Schering-Plough Corporation, and AstraZeneca Pharmaceuticals LP.
  • ,
  • Allison A. Petrilla, MPH

      Affiliations

    • IMS Health, Inc., Arlington, Virginia, USA
    • Ms. Petrilla and Ms. Goel are consultants to IMS Health, Inc, and Ms. Petrilla is a former employee of IMS Health, Inc.
  • ,
  • David Klingman, PhD

      Affiliations

    • IMS Health, Inc., Arlington, Virginia, USA
    • Drs. Benner, Smith, and Klingman are all employees of IMS Health, Inc, a health information services and consulting firm. They have provided consulting services to manufacturers of antihypertensive and lipid-lowering therapies, including Pfizer Inc., Schering-Plough Corporation, and AstraZeneca Pharmaceuticals LP.
  • ,
  • Sangeeta Goel, PharmD

      Affiliations

    • IMS Health, Inc., Arlington, Virginia, USA
    • Ms. Petrilla and Ms. Goel are consultants to IMS Health, Inc, and Ms. Petrilla is a former employee of IMS Health, Inc.
  • ,
  • Simon S.K. Tang, MPH

      Affiliations

    • Pfizer Inc., New York, New York, USA
    • Mr. Tang is an employee of, and holds stock options for, Pfizer Inc.
  • ,
  • Nathan D. Wong, PhD

      Affiliations

    • Heart Disease Prevention Program, Division of Cardiology, University of California, Irvine, California, USA
    • Dr. Wong receives grant support from Pfizer Inc., and Bristol Myers Squibb, and is on the speakers’ bureau for Pfizer Inc., Sanofi-Aventis, and Takeda. The staff of IMS Health were paid consultants to Pfizer Inc., in connection with the development of this article.

Received 10 April 2007 ,Accepted 10 July 2007.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 This study was supported by a Grant from Pfizer, Inc.

PII: S1933-1711(07)00158-1

doi: 10.1016/j.jash.2007.07.001

Journal of the American Society of Hypertension
Volume 2, Issue 1 , Pages 44-53 , January 2008